Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data BetterLife Pharma Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2009
FY2010
FY2011
FY2011
FY2012
FY2016
FY2016
FY2017
FY2018
Research and development
0.06
0.07
General and administrative
0.06
0.07
0.02
0.03
7.7
1.6
0.34
Operating expenses
0.12
10.3
6.02
1.05
Operating income
-0.12
-10.3
-6.02
-1.05
Interest expense
-0.06
-0.02
0.06
0.01
0.03
Other non-operating income
-2.88
1.78
0.43
Pre-tax income
1.13
10.3
6.33
0.12
Income from continuing operations
-0.14
-0.36
-0.09
Net income
-0.65
-0.12
-3.02
1.42
0.34
-1.13
-10.3
-6.28
-0.12
EBITDA
-0.12
-10.3
EPS, basic
-0.10
-0.11
-0.08
0.00
EPS, diluted
-0.10
-0.11
-0.08
0.00
Shares, basic (weighted)
28
33.9
35.8
11.6
77.7
75.3
79.9
Shares, diluted (weighted)
28
33.9
35.8
11.6
77.7
75.3
79.9
Balance sheet
FY2009
FY2010
FY2011
FY2011
FY2012
FY2016
FY2016
FY2017
FY2018
Cash and equivalents
0.02
0.02
0
0
0
0.07
0.11
0.06
Other current assets
0
0.03
0.02
0.08
Total current assets
0.02
0
0
0
0.1
0.13
0.15
Property, plant and equipment
0
0
0
0
Intangible assets
0.23
Total assets
0.02
0
0.01
0
0.11
0.13
0.38
Total current liabilities
0.13
0.87
0.66
0.44
1.61
0.43
Total liabilities
2.97
1.03
0.68
0.06
0.44
1.61
0.43
Paid-in capital
0.05
0.17
0.17
0.26
6.17
11.2
11.8
Retained earnings
2.16
-4.01
-14.3
-20.6
-20.7
Other comprehensive income
0.22
0.75
0.58
0.59
Shareholders' equity
0.03
0
-2.95
-1.02
-0.67
-0.05
-0.33
-1.47
-0.05
Total equity
0.03
0
-2.95
-1.02
-0.67
-0.05
-0.33
-1.47
-0.05
Total liabilities and equity
0.02
0
0.01
0
0.11
0.13
0.38
Shares outstanding
35.8
65.9
74.7
75.6
82.4
Cash flow statement
FY2009
FY2010
FY2011
FY2011
FY2012
FY2016
FY2016
FY2017
FY2018
Net income
-0.65
-0.12
-3.02
1.42
0.34
-0.98
-9.79
-6.44
-0.12
Depreciation and amortization
0
0
Stock-based compensation
0.01
5.91
5.02
0.05
Change in payables
0.01
0.08
0.03
0.09
0.1
0.57
0.53
Cash from operations
-0.11
-0.14
-0.03
-0.05
-0.16
-0.36
-0.4
Cash from investing
-0
Debt repaid
0.15
Stock issued
0.04
0.24
0.32
Cash from financing
0.11
0.12
0.03
0.05
0.24
0.38
0.36
Interest paid
0.01
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to October 31, 2018; growth uses fiscal years. Valuation uses the share price of $0.22 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-196.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-95.2%
Net income / average total assets.
Return on invested capital (ROIC)
-114.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
189.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
572.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
6.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
90.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.15x
Current assets / current liabilities.
Quick ratio
0.11x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.11x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.04
Cash from operations / diluted weighted shares.
Book value per share
$0.04
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
9.42x
Market cap / shareholders' equity. Only when equity is positive.
Earnings yield
-20.9%
Net income / market cap (the inverse of P/E).
Was BetterLife Pharma Inc. profitable in fiscal 2018?
No. It reported a net loss of $121.2K.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.